Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers after Oral Doses of Saxagliptin

Study identifier:D1680C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open label, Pharmacokinetic Study of Single and Multiple Doses of 5 mg Saxagliptin in Healthy Chinese Subjects Living in China

Medical condition

Type 2 Diabetes

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Saxagliptin

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Oct 2008

Primary Completion Date: 01 Oct 2008

Study Completion Date: 01 Oct 2008

Study design

Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Bristol-Myers Squibb

Inclusion and exclusion criteria

Location

Research Site

BEIJING, China

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1186&filename=CSR-D1680C00004.pdf
Download
CSR-D1680C00004.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Peter Öhman

AstraZeneca